ArticleBMC microbiology2026
Evaluation of antifungal activity, mechanism of action, and zebrafish toxicity of N-(3-fluorobenzyl)-N,3-dimethylbut-2-enamide.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTo address the urgent need for novel green fungicides in eco-friendly plant disease control, this study involved the evaluation of N-(3-fluorobenzyl)-N,3-dimethylbut-2-enamide. The work aims to provide a solid theoretical and data-driven foundation for elucidating antifungal mechanisms, and assessing the ecotoxicological risks associated with this substance.
methodsThis study encompassed the bio-evaluation of the compound N-(3-fluorobenzyl)N,3-dimethylbut-2-enamide, specifically its antifungal activity (against 13 fungi via poisoned food and mycelial growth rate methods, with MIC for, Monilinia fructigena), multi-target mechanism (via ultrastructure, carbon metabolism, TCA cycle enzymes, and energy substances), and ecotoxicity in zebrafish embryos (LC50, morphological defects, and effects on hematopoiesis and cardiac development).
resultsN-(3-fluorobenzyl)-N,3-dimethylbut-2-enamide exhibited concentration-dependent antifungal activity against all 13 tested plant pathogenic fungi, showing the highest inhibition rate (79%) against M. fructigena at 20 mg/mL, with a minimum inhibitory concentration of 4.69 μL/mL. Investigation into its mode of action revealed multi-target synergistic effects: it disrupted fungal cell ultrastructure, induced carbon metabolism disorder (increasing soluble sugars by 52.1% and reducing sugars by 71.4% while decreasing soluble protein by 14.0%), inhibited key TCA cycle enzymes (reducing SDH and MDH activities by 27.2% and 37.0%, respectively), and depleted ATP while disrupting the NADH/NAD⁺ balance, collectively leading to energy metabolism collapse and cell death. In ecotoxicity assessment, the compound (denoted as compound A) demonstrated significant concentration-dependent toxicity in zebrafish embryos, with an LC₅₀ of 75.42 mg/L and 100% mortality at 96.0 mg/L. It also induced morphological abnormalities including pericardial edema, tail curvature, and axial shortening (p<0.01), suppressed hematopoietic stem cell generation, and caused linearized cardiac chamber stretching.
conclusionsThe findings of this study provide a solid scientific foundation for the molecular optimization, in-depth investigation of antifungal mechanisms, and systematic ecological risk assessment of this class of green amide fungicides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.